Book Review: The Essentials of Patent Claim Drafting

January 8, 2012

The Essentials of Patent Claim Drafting by Morgan D. Rosenberg is a straightforward practical guide to drafting claims, aimed at the beginner. To the extent that one can learn to draft claims from a book, this is not a bad tutorial.

As with many such works however, it is strongly biased to mechanical type drafting. Software and physics are covered to some extent, but the focus is heavily on the predictable arts. The claim style is a little long-winded and pedantic for my taste. The focus is on USPTO requirements, but nevertheless, in my opinion, a chapter dedicated to the differences in US approach, from say, that of the EPO, would be a valuable addition.

The thrust is on drafting claims for obtaining patents. System, Method, product-by-process, Jepson, Markush and Beauregard  claim styles are discussed and illustrated, as are means+function, which are discouraged. Free Beer claims are not mentioned unfortunately. Nor are other claim styles disallowed in the US such as omnibus claims.  Since ultimately a patent might be litigated, there should perhaps be some discussion on claim construing in Marksman hearings and the need to make sure that terms cannot be misinterpreted.  Nevertheless, a useful guide for beginners.

  • Paperback: 224 pages
  • Publisher: Oxford University Press, USA (November 17, 2011)
  • Language: English
  • ISBN-10: 0199856354
  • ISBN-13: 978-0199856350
  • $125

America Invents at Bar Ilan University

January 5, 2012

Yesterday, I had the privilege to attend a very well run and well constructed full day program dedicated to the America Invents Act. The highlight of the program, was, without a doubt, a lecture by Judge Randall Rader, the Head of the US Federal Circuit Court of Appeals.  Judge Rader is in the enviable position that his interpretation of the amendment to the patent law is likely to prevail when they are litigated. This is reason enough to hear him. Additionally, Rader is an accomplished speaker and his presentation was highly entertaining.

Rader started by wishing everyone a Good Year (Shana Tova) in heavily accented Hebrew, but then noted that it wasn’t actually the Jewish New Year at all. He went on to say all sorts of nice things to the appreciative audience, about Israel being heavyweight patent filer despite its small population, and that Israelis have a survivalist mentality that serves them well in the modern era of fierce global competition.

The main thrust of Rader’s presentation focused on what he saw as being the central issue of the America Invents Act; that America becomes a first-to-file regime, abandoning their anomalous first-to-invent system, thereby coming into line with the rest of the world. However, Rader noted with satisfaction, that the grace-period has been retained. In his opinion, this protects inventors from killing their patenting chances by first publishing or demonstrating their innovations. Rader expressed his hope that now that the US had made a massive move towards Europe in adopting the first to file regime, that perhaps Europe should reciprocate by also adopting a grace period.

Rader invited questions from the audience, and it seemed that many of those present were less than convinced that the judge was correct that the amended law reduced uncertainty and really promoted greater similarity between countries. I pointed out that as far as both novelty and inventive step (obviousness) are concerned, there was still significant differences. My good friend Larry Rublin made a short and succinct observation that made it apparent that he was proficient at defining systems, as would be expected from a patent attorney. In contrast to most of the audience, Larry’s mentor, Heidi Brun, went on record to the effect that she believed that the grace-period was positive, since it gave something to tell the inventor who had already exhibited.

I found myself realizing that my preference for first-to-file was that it provided certainty based on simple to establish facts.  Judge Rader apparently believes that patent protection is a reward for inventing and contributing to knowledge, and so the uncertainty that prior publication brings should be allowed, despite it somewhat complicating the system. I suspect that Heidi’s position reflected both her personal empathy with the inventors and also the patent attorney’s (self) interest to enable clients to protect their IP. Another reflection that came to me whilst listening to Judge Rader, was how unfortunate it is that Israel does not have dedicated IP judges. The final thought, seeing Rader’s stars and stripes necktie, and the green with white polka dot thing wore by sponsoring attorney Colb, was that there is apparently a correlation between the eminence of the speaker, and the ridiculousness of the tie.

The pastries served during the coffee break were freshly baked and delicious, and there was a selection of both tea and herbal infusions. Disappointingly, the coffee was either instant or botz (hot water poured over ground coffee).  Nevertheless, the speakers were sufficiently interesting that quality caffeine wasn’t necessary to stay awake.

Judge Rader was followed by a light-hearted but thought provoking presentation by Dr Dan Goldstein and Benjamin Fishman, both senior patent attorneys at Colb, each wearing formal business suits and fairly conservative ties. They proposed a number of reasonable scenarios and amply demonstrated that the law, as legislated, left a lot of uncertainly, and presumably the courts will have their work cut out over the next few years. Judge Rader was teased a little in the presentation, but he took it well, and showed his sharp legal mind  in one of his responses, by succinctly distinguishing between the aspects of the scenario presented that were a consequence of the new legislation, and the aspects that were equally problematic under the old law, or simply due to the complications of plausible, if convoluted, scenarios.

After lunch, comprising filled rolls and an orange vegetable soup, the program continued with sessions compered by Dr Yoav Mazeh and Dr Ofer Tur-Sinai, young lecturers at ONO Academic College, showing a nice collaboration between the two closely situated law faculties.

Colb himself spoke about the statistics of reexamination and came to the conclusion that after investing large sums of money, most clients obtain a patent that if they tried to enforce, would be invalidated or at least considerably narrowed, and suggested that attorneys should tell their clients.

Dr Ofer Tur-Sinai chaired the final session. David Zviel, Patent Counsel of NDS, spoke about the ethical conflicts faced by in-house counsel. David argued that the pressure resulting from dealing with ethical dilemmas faced by pin-house counsel were greater than those faced by attorneys working for patent firms. Unfortunately, for obvious reasons, he didn’t illustrate this assertion with concrete examples.

Professor Orli Lobel cut an impressively elegant figure in a well tailored jacket, and stylish designer jeans. For some reason she postulated that it was easier for a large corporation to make a decision and to pursue a policy than it was for an independent inventor. She backed up her position with some empirical evidence culled from the effect of the reform to the Canadian patent law that was in some ways similar to the American Invents Act. Her presentation was followed by one by Suzanne Erez, in-house IP counsel for IBM Israel, who wore a more homely knitted dress and flat shoes, and who walked around a lot whilst presenting. It was not clear whether she was gently poking fun at the earlier and mre formal speakers, or if Suzanne simply and justifiably felt at home with the audience of her peers, and felt no need to dress to impress. She focused on key issues that the act could and should have related to. All the presenters significantly contributed to the program and even without Judge Rader’s keynote presentation, the day would have been informative and worthwhile.

The event attracted about 100 people, and for Judge Rader’s presentation, the lecture hall was packed,  with people standing in the aisles.

This was the fourth such annual event hosted by Bar Ilan University and co-sponsored by the Jerusalem College of Technology and S. T. Colb Patent Attorneys. Although the food served at last year’s conference, held at the Tel Aviv Hilton was of a higher quality,  in my opinion that program, featuring attorneys from Fish Richardson was a little too commercially oriented for academic institutions like Bar Ilan and JCT to be identified with, despite being of a high standard.

It was certainly a better program than that offered the year before where the Bar Ilan – Colb collaboration examined the future of business method patents  after Bilski, despite pre-empting the decision it was supposed to analyze. It also featured too many academics having little knowledge of real patent issues.

In summary, this year’s program was informative, topical, well organized, well attended and thoroughly enjoyable. I congratulate all the speakers, and thank Professor Bitton, Seth Heller and Sanford Colb for organizing the event. We note with pleasure that Professor Arieh Reich, the Dean of the Bar Ilan Law Faculty announced that this January IP event would continue to be held annually.


America Invents, and you can learn about it in Israel!

December 18, 2011

Bar Ilan university are hosting a full day conference on 4 January 2012 to debate the ramifications of the changes in the US Patent Law wrought by the America Invents Act.

To register, or to receive more details, please contact Dr Miriam Bitton:   miriam.bitton@mail.biu.ac.il

The event is sponsored by S.T. Colb and will be held in the Wohl Center, Hall 1 of the Bar Ilan Campus.

The program hasn’t been released yet, but apparently Judge Randall Rader the Chief Judge of the United States Court of Appeals for the Federal Circuit will be lecturing, so regardless of who else is presenting, the event will be worth attending.

COMMENTS

Two years ago, the dynamic Bitton-Colb duo gave us a conference titled, After Re Bilski Now What? which unfortunately took place several months before the Bilski decision was heard by the Supreme Court.  See  here. That conference, spread over two days, was characterized by a lot of vacuous waffle and prophecies that never materialized. We therefore applaud the decision to concentrate on recent historical (and perhaps historic) amendments to the US Law.

In January last year, S.T. Colb teamed up with Fish Richardson and held an event on patent litigation in the US. That event was again cosponsored, at least officially, by Bar Ilan.  For more details, see here.

We suspect that the refreshments at Bar Ilan will be less of a high standard, but lower than the fayre at the Hilton. Looking forwards.


Camtek wins Appeal Against Rudolph

August 23, 2011

 

 

The Federal Circuit Court of Appeals has cancelled a District Court ruling, following a jury decision, that Camtek infringed patents held by Rudolph, a German competitor (now August).

In the original ruling, Rudolph was awarded $8.7 million in damages and a permanent injunction against Camtek.

The Federal Circuit Court of Appeals has found that the District Court erred in the construction of a key claim term and vacated the finding of infringement, the damages award and the permanent injunction.  The case has been remanded to the District Court for a limited trial based on the corrected claim construction.

For more details: http://www.prnewswire.com/news-releases/camtek-wins-appeal-of-the-decision-in-rudolph-patent-infringement-case-128232213.html

Equitable Disclosure: Although I’ve had nothing to do with the case in question, I have performed some opinion work for Camtek, which is an Israeli company, and have also drafted and prosecuted a number of patents for Amitek, a sister company.

 

 

 


Viagra patent holds up

August 17, 2011

Teva’s challenge to the validity of Pfizer’s patent for Viagra was dismissed by U.S. District Judge Rebecca Beach Smith of Norfolk, Virginia, in a 110 page opinion.

 

“Teva has not shown by clear and convincing evidence that the patent is invalid,” wrote Smith who went on to state that “There is utterly no evidence” to support Teva’s claim that Pfizer intentionally withheld documents from the U.S. Patent and Trademark Office. For more information see http://www.bloomberg.com/news/2011-08-15/pfizer-wins-viagra-patent-infringement-case-against-teva-pharmaceuticals.html

 

 

 

 

 


Thesaurus of Claim Construction – a book review

March 4, 2011

I was very excited when Stuart Soffer, a Non-Resident Fellow, Stanford Law School Center for Internet and Society informed me of his forthcoming book, “Thesaurus of Claim Construction” which is co-authored with Robert C. Kahrl, a long term partner at Jones Day. Such a book is long overdue.

The nice people at Oxford University Press kindly sent me a copy.

The work is mostly an alphabetic arrangement of words and phrases that have been construed in the course of patent litigation and includes over 7000 entries. Since such constructions are, by definition, rulings regarding the meaning of the word or phrase in the specific context. Consequently such constructions are not binding precedents and aren’t even much use as an indication of what a phrase would be interpreted to mean in another claim construction. Nevertheless, the definitions do show what the words could be taken to mean.

The range of words and phrases that have been the subject of claim construction may be surprising to some. Chief Judge Markey in Senmed vs. Richard Allan Medical Industries, Inc 888 F.2d 8215, 819 n. 8 (1989) commented on a construction of the word ‘on’ in a claim, that;

 ”lawyers may create a dispute about any word”.

Chapter 1, ‘How to use this book’ is well worth reading, but I rarely bother with user manuals and certainly have no intention to review a user manual for a book, so will move on.

Chapter 2, titled ‘Outline of the Law of Claim Construction’ is a must read for litigators and is valuable reading for practitioners drafting claims. Personally, I believe that expensive disputes could be avoided by using words more carefully, preferably in accordance with their regular meanings and with definitions in the specification. Nevertheless, it is valuable to review the hierarchy between dictionary definitions, the specification, extraneous sources and the file wrapper. There are also differences in how the preamble, transitional phrases and limiting clauses are interpreted. It is useful to remember that the correct construction is what the word meant at the time of filing, apart from the cases where limitations crept in during prosecution.

The lion’s share of the book is devoted to Chapter 3, an alphabetical list of “Simple terms” that have been construed at some time or other, with indications of which definition and which party prevailed and which constructions were rejected. The entries are referenced with the details of the court dockets for further reference.

The list starts with a construction of the symbol %, and reminds us that compositions should be given as weight percent, or volume percent, and that it should be clear if the percentage is of the total composition, or of only part. The next words to be examined are ‘a’ and ‘the’. One can understand why a term like ‘AC energy’ required construction as it is ambiguous, since current is measured in amps and energy in joules, but who would have the foresight to define whether ‘AC wave’ implies the wave created by a varying current over time, or whether the direction of the current has to keep reversing? Likewise the effect of adding words like ‘about’ in a claimed range becomes clearer on reviewing the way such claims are construed.

It will be appreciated that words beginning with letters B through Z have also been construed and this review is not intended to comment comprehensively on all the entries. One can amuse oneself by opening randomly and seeing what terms have been discussed though. For instance, in a particularly adolescent moment I discovered how the court interpreted the term nipple cover.

 In Allure Home Creations vs. Zak, the term ‘second vessel’ was interpreted to mean ‘a preformed sealed vessel enclosing a first liquid and an insoluble structure floating on the first liquid. One presumes, therefore, that the context had nothing to do with first and second vessels relating to reheating foodstuffs on the Jewish Sabbath without violating the Biblical prohibition of cooking – tha is unless the claimed invention related to chicken soup with kneidlach (matzo balls).

One of my esteemed Israeli competitors has the endearing habit of defining the word plurality to mean ‘one or more’ in his specifications. Native English speakers working for him have been unable to convince him that this is simply wrong. I was pleased, therefore to see that the many constructions of the word plurality all take the word to mean at least two. Nevertheless, one wonders how his claims would be construed.

The book relates to litigation in the US, but, since the US is an important market, and because judges everywhere seem to have little scientific aptitude and lawyers everywhere play semantic games, the book will appeal to an international audience. 

In addition to giving the history of Marksman there is also a valuable chapter on ‘means + function’ claims and how they are construed.  Apart from guiding litigators, the book may help claim drafting, should help designing around, and will prove invaluable to practitioners required to express opinions about the work of others. It is also an impressive addition to one’s shelf of dictionaries and reference books, since it has approximately similar dimensions to standard editions of Roget’s prior art.

Thesaurus of Claim Construction, Robert C Kahrl and Stuart B. Soffer, Oxford University Press 2011. Well worth the $295 asking price.


The moral rights of a sculptor to be identified with his work

September 12, 2010

David Ascalon, an Israeli-born sculptor living in New Jersey whose grandparents were murdered in the Holocaust, was commissioned to create a Holocaust memorial in 1993 by the Jewish Federation of Greater Harrisburg.

His design consists of a stainless-steel Star of David base in which a series of stainless-steel poles are mounted. These are bound up by a dark, rusty-looking metal “spiral serpent” that resembles barbed wire.

The 15-foot-tall sculpture was placed in a park, and Ascalon was paid $35,000 for the work.

Apparently, the stainless steel core represents the Jewish people because stainless steel has an eternal look. The decayed serpentine rusting shape on the other hand, symbolizes the Nazis.

However, Within 10 years, the Holocaust sculpture needed repairs, because the barbed-wire serpent had become overly rusted. Mr. Ascalon volunteered to do the restoration, asking only to be reimbursed for the costs.

In 2006, the Parks and Recreation Department of Harrisburg chose a restorer who replaced the original barbed-wire motif with a shining stainless steel replica and scratched out Mr. Ascalon’s name from the memorial’s base, replacing it with his own.  It now says “Restored by David Grindle 2006” and lists the names of the “Restoration Advisors.”

What’s more, a lawyer for the Jewish Federation demanded that Mr. Ascalon stop claiming to be the memorial’s artist.

In July, Mr. Ascalon filed a lawsuit in U.S. District Court against the parks department, the Jewish Federation and the restorer for violating his moral rights.

According to the Statement of Claim

“The modification of the sculpture has changed it so that now the same shiny stainless steel that represents the enduring Jewish people is also used to depict the Nazi regime and atrocities of the Holocaust. This alteration is abhorrent, and runs completely contrary to the core vision of the Memorial, which was based on the notion of creating a striking and stark visual contrast between the Jewish people and their Nazi oppressors. The sculpture as modified now creates a visual equivalency between good and evil, which is a mutilation and bastardization of the artwork and its purpose.”

The case is an interesting one. The choice of materials, including the rusting barbed wire, was done intentionally. Changing these arguably compromises the artists moral rights. On the other hand, shouldn’t the purchaser of a piece of art be able to make improvements, like stopping it disintegrating away?

The restorer may have the moral right to be accredited, but surely the original artist has rights as well?

Once the sculpture is changed and the name of the original artist is no longer mentioned, arguably his moral rights are no longer compromised.

According to Visual Artists Rights Act 1990 (VARA), incorporated into the Copyright Act as  § 106A(a)(2) of the Visual Arts , the author of a work of visual art  “shall have the right to prevent the use of his or her name as the author of the work of visual art in the event of a distortion, mutilation, or other modification of the work which would be prejudicial to his or her honor or reputation.”

If the adapting of the original art is done concurrently with removing the name of the artist, arguably his moral rights are not compromised.

I think the original artist deserves credit for his creation, but the purchaser should have the right to make such alterations as are required for practical reasons, and perhaps for aesthetic ones as well, but these should be clearly documented on site. Thus attributing the restorer with details of his restoration is legitimate but this should flag the fact that the integrity of the original creation was compromised and that the work on display has been modified.

Such a solution may not be acceptable to all parties. The sculpture is large and imposing. Any documentation on site will, of necessity, be less so. 

I suppose if those that daub graffiti on holocaust memorials, such as that in Hyde Park London, would have the integrity to identify themselves for prosecution purposes, that would be a good thing as well.

It is a shame that such cases are not settled amicably.


Teva Suspends Litigation to Invadidate Eisai’s Compound Patent for Drug Aricept

July 21, 2010

Teva Pharmaceuticals USA Inc. has agreed to suspend litigation over a compound patent for Eisai Co. Ltd.’s popular Alzheimer’s drug Aricept, thereby ending Teva’s attempts to manufacture and market a generic version of the drug before the patent expires in November.

Judge Garrett E. Brown Jr. of the U.S. District Court for the District of New Jersey signed off on the agreement Monday, and called for the case to be dismissed after the patent expires. However, the March 2008 preliminary injunction prohibiting Teva from manufacturing drugs including ingredients covered by the patent remains in effect.

Teva filed an abbreviated new drug application with the U.S. Food and Drug Administration in 2008, and, when sued by Eisai, initially claimed that the patent was invalid due to obviousness, and later changed defence to claim inequitable conduct.

Teva had asked for communications not related to the patent-in-suit, but to seven co-pending patent applications that it claimed Eisai failed to disclose to the patent examiner in charge of the application that led to its Aricept patent-in-suit.

In December, Magistrate Judge Esther Salas denied Teva’s motion to compel discovery for its inequitable conduct defense. Teva, which sought communications between Eisai and the U.S. Patent and Trademark Office, appealed to Judge Brown, but he affirmed Judge Salas’ order in June, that concluded that the generics maker’s discovery request was too broad and unduly burdensome.

Teva also sought discovery of communications between Eisai and the USPTO related to any abandoned patent applications that involved derivatives of benzylpiperidine, the active chemical in Aricept, on the grounds that they also might contain information to support the inequitable conduct defense. But Judge Salas said the patent applications were outside the scope of the companies’ current dispute and that expanding the search to include abandoned patent applications would “be a burden that outweighs the benefits to Teva.”

The patent-in-suit is U.S. Patent Number 4,895,841.

The case is Eisai Co. Ltd. et al. v. Teva Pharmaceuticals USA Inc. et al., case number 05-cv-05727, in the U.S. District Court for the District of New Jersey.


Finnegan Patent Litigation Seminar in Israel Sets New Standards

June 27, 2010

Jeffery Berkowitz and Gerson Panitch, partners at Finnegan, Henderson, , Garrett & Dunner, LLP.,  presented a two-day seminar at the Dan Accadia Hotel, Herzliya. The seminar, which ran over the 23rd and 24th of June 2010, was attended by a couple of dozen in-house IP Counsel from Israeli industry, and by three or four patent attorneys from leading IP Law firms.

The course covered pre-litigation analysis, forum shopping, cease and desist letters, discovery, depositions, settling out of court, dismissal before trial, selecting a jury and winning in court, with the appeal process also discussed.  The course succeeded in what it set out to do, i.e. to educate a sophisticated and intelligent IP Savvy audience about the litigation process in the US.

The audience included IP counsel of Israeli firms such as Red Bend that were in the process of litigating against corporate giant Microsoft, companies such as Nuvoton that have been stung by non-practicing entities (sometimes called trolls), and the IP counsel of Nice Software Systems that has given depositions and had some familiarity with the system.

It is and always has been clear that patent litigation in the US is an expensive business that is not for the faint-hearted. After this seminar, most participants had a better idea of where the money went. Like a Hollywood production, there are script-writers, researchers and stars that need paying.

Jeffery Berkowitz and Gerson Panitch are both very competent lecturers and appear to be very pleasant and personable. I imagine that this helps them in both depositioning and cross-examining witnesses. 

Despite costing a wacking $1000 per person, I think everyone was very satisfied that they got value for money, as we all came away with a better understanding of US Litigation.  The food was excellent, with a generous breakfast and a gourmet three-course buffet lunch being provided, with croissants as a mid-morning snack and an extravagant fruit platter in the afternoon.

The event was hosted by Kim Lindy’s latest initiative – the IP Resources Ltd.

Over the summer, speakers from Finnegan will be lecturing on a weekly basis at the Law Offices of Eitan Mehullal in a series of seminars sponsored by the IP Law Department of Haifa University. Warmly recommended.


South Butt Settles With North Face

June 27, 2010

 A student,  Jimmy Winkelmann, started a clothing company for the less outdoor types. Calling his company the South Butt, he used the logo of outdoor sports clothing company the North Face, and his logo, though reminiscent of a butt (i.e. a pair of buttocks) is not dissimilar to the North Face’s famous logo, though rotated through 180 degrees.

Not surprisingly, the North Face sued. Corporate giants don’t seem to have much of a sense of humour. However, instead of backing down, Winkelmann fought back. The two sides have reached an out of court settlement, the details of which are confidential. What is clear, however, is that the South Butt are still very much in business, and have only gained from the publicity that the North Face’s law suit gave them. Essentially, a local college store has become big business.

Victoria’s Secret eventually won against Victor’s Little Secret, but the sex shop seems to have benefitted from the publicity over a long period of time. The Naked Cowboy who plays guitar in his under-pants in Time Square is suing the Naked Cowgirl who does the same thing in a bikini. She has assets that he doesn’t. I suspect that he may lose a lot of the good PR from his case against M&M where, rumour has it, he paid legal fees for both sides.

 Some cases are lose-lose – like when Johnson and Johnson sued the American Red Cross for using a red cross logo. The moral of the story seems to be – pick your battles.


Follow

Get every new post delivered to your Inbox.

Join 93 other followers